Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several mechanistic and interaction claims align with the provided label (CYP3A4 metabolism, grapefruit juice increases atorvastatin plasma concentrations via CYP3A4 inhibition). However, multiple timing/duration and dosing-behavior recommendations are not supported by the supplied label excerpts, and some specific details about the interaction (furanocoumarin absorption, last “for several hours,” and 12–24 hour waiting guidance) are not found in the provided sections.
Category Scores
Accurate Statements
Grapefruit and grapefruit juice contain components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters/day).
7.2 Grapefruit Juice; also 7.1 and 7 Drug Interactions
CYP3A4 is responsible for metabolizing Lipitor/atorvastatin (LIPITOR is metabolized by cytochrome P450 3A4).
7.1 Strong Inhibitors of CYP 3A4
Concomitant administration of LIPITOR with strong CYP 3A4 inhibitors can lead to increases in plasma concentrations of atorvastatin.
7.1 Strong Inhibitors of CYP 3A4
Unsupported Statements
Furanocoumarin is absorbed into the bloodstream after eating grapefruit or drinking grapefruit juice.
The provided label excerpt (7.2 Grapefruit Juice) states grapefruit juice contains components that inhibit CYP3A4 and can increase plasma concentrations, but does not describe furanocoumarin absorption.
Furanocoumarin can inhibit the enzyme CYP3A4.
The label excerpt attributes the effect to grapefruit juice components inhibiting CYP3A4, but it does not identify furanocoumarin specifically.
Inhibiting CYP3A4 can increase the levels of Lipitor in the bloodstream.
While the label supports increased plasma concentrations with CYP3A4 inhibition, it does not explicitly state this as a general causal statement in the provided excerpt; support is indirect via 7.1/7.2.
Increased Lipitor levels in the bloodstream can increase the risk of side effects.
The provided label excerpts do not state that increased plasma concentrations (from CYP3A4 inhibition/grapefruit) increase the risk of side effects.
The grapefruit-Lipitor interaction can occur within 1–2 hours after taking Lipitor.
The provided label excerpt with 1–2 hours pertains to atorvastatin maximum plasma concentrations after absorption (12.3), not to grapefruit interaction timing.
The effects of the grapefruit-Lipitor interaction can last for several hours.
No duration of grapefruit interaction effects is provided in the supplied label excerpts.
It is best to wait at least 12–24 hours after taking Lipitor before consuming grapefruit or grapefruit juice.
The provided label excerpt on grapefruit does not provide a wait-time recommendation.
Grapefruit juice is a more concentrated source of furanocoumarin than fresh grapefruit.
No comparison of furanocoumarin concentration between juice and fresh grapefruit is provided in the supplied label excerpts.
It is best to avoid grapefruit juice altogether if taking Lipitor.
The label excerpt specifically highlights increased concentrations with excessive grapefruit juice consumption (>1.2 liters/day) and does not state “avoid altogether.”
Diluting grapefruit juice with water or another juice can reduce the amount of furanocoumarin in the juice and minimize the risk of interaction.
No dilution mitigation guidance is provided in the supplied label excerpts.
Contradictions
Important Omissions
The label excerpt provides a specific threshold for grapefruit juice consumption (>1.2 liters/day) associated with increased atorvastatin plasma concentrations; the response does not mention this threshold.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Mechanistic points about CYP3A4 metabolism and grapefruit increasing atorvastatin plasma concentrations are consistent with the provided label. However, unlabelled timing/duration and the prescriptive “avoid altogether”/“12–24 hours” guidance may mislead behavior beyond what the supplied label excerpts support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several grapefruit interaction details (furanocoumarin identification/absorption, timing/duration, and specific avoidance/wait-time/dilution recommendations) are not supported by the provided LIPITOR label excerpts.
Suggested Improvement
Limit interaction statements to what the label excerpt supports: grapefruit juice components inhibit CYP3A4 and can increase atorvastatin plasma concentrations, especially with excessive grapefruit juice consumption (>1.2 liters/day). Remove or reframe unsupported specifics (furanocoumarin absorption, interaction timing within 1–2 hours, “several hours” duration, 12–24 hour waiting period, avoid altogether, and dilution mitigation).